Ozempic Works. The Part No One Talks About Is What Happens When You Stop.

Article

GLP-1 drugs are a real breakthrough. But the goal was never a number on the scale — it was a metabolism that holds without the drug. That's the harder problem. Let me say the obvious first: GLP-1 drugs work. Semaglutide and tirzepatide have produced weight loss that a decade ago we'd have called impossible with medication — and for many people at real metabolic risk, they've been genuinely life-changing. I'm not here to argue otherwise. But the entire conversation is fixated on one half of the story: starting. Almost no one is talking about the other half — what happens when you stop. And the data there is sobering. What the trials show when the drug comes off Start with semaglutide. In the STEP 1 trial, people lost an average of about 17% of their body weight. Then researchers followed a group after they came off the drug. One year later, they had regained roughly two-thirds of what they'd lost — and the improvements in blood pressure, blood sugar, and lipids largely reversed right along with it. The gains, it turned out, were rented, not owned. And it isn't a semaglutide quirk. In SURMOUNT-4, which tested tirzepatide, most people who stopped regained substantial weight — over 80% had regained at least a quarter of their loss within about a year — and, again, the cardiometabolic improvements faded as the weight came back. Two different drugs, the same pattern: the results depend on staying on the drug. Why it happens The reason is in how these drugs work. A GLP-1 quiets appetite and shifts your hunger set-point while it's in your system. It is doing the work. The moment you stop, the biology it was overriding — the appetite signals, the drive to eat — comes back. If nothing underneath actually changed, the body simply resumes the trajectory it was on. The drug didn't rebuild your metabolism. It borrowed you a result. A GLP-1 rents you a result. It doesn't buy you a working metabolism. And not all of the lost weight is fat. There's a second, quieter issue. By some analyses, a meaningful share of the weight lost on these drugs — up to around 40% in certain studies, though estimates vary widely and much of it reflects the body's normal adjustment to being smaller — is lean mass, including muscle. That matters for the off-ramp specifically, because muscle is metabolically active tissue: lose too much of it and you lower your metabolic floor, which makes weight easier to regain and the drug harder to leave. It's why researchers increasingly stress protein and resistance training alongside these medications — how you lose the weight shapes how well you keep it off. The real goal was never the scale Put it together and the actual problem comes into focus. The goal was never a number on a scale. It was a metabolism healthy enough to hold on its own. Losing the weight is step one — and the drugs are extraordinarily good at step one. Keeping the metabolic gains after the drug is the step the conversation skips, and it's the harder one. Use the window The reframe I'd offer isn't anti-drug — it's the opposite. A GLP-1 opens a window: appetite is quiet, momentum is real, and the hardest part of behavior change is temporarily easier. That window is precisely when you build the foundation that lets the result survive the drug — protecting muscle with protein and training, and building the food and lifestyle patterns that keep your body's insulin demand low, so your metabolism isn't fighting you when the drug comes off. And you plan the off-ramp from thestart, with your physician — tapering deliberately and watching how your body responds as the drug's effect fades, rather than treating the day you stop as an afterthought. (Understanding how your own body handles food as you wean off, so the progress sticks, is exactly the kind of metabolic feedback we care about at Aleré — but that's a longer story for another day.) The honest version GLP-1 drugs are among the most powerful tools we've ever had for weight and metabolic health — and they are a tool, not a cure. The cure, if there is one, is the metabolism you rebuild underneath while the tool is doing its work. Start the drug already thinking about the off-ramp, and the odds it actually lasts go up. So a question, especially if you're on a GLP-1 or considering one: have you thought about theafter— the off-ramp — as much as the start? I'd really like to hear how people are approaching it. I'm an engineer and applied physicist, not a physician — and GLP-1 medications are powerful drugs. This is education, not medical advice. Never start, stop, change, or taper any medication without your own doctor; decisions about GLP-1 therapy belong with you and your clinician. References Wilding JPH et al., “Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension,” Diabetes, Obesity and Metabolism 2022 (~two-thirds of lost weight regained one year after stopping). SURMOUNT-4 (tirzepatide withdrawal): weight regain and reversal of cardiometabolic gains — trial results and JAMA Internal Medicine 2025 post hoc analysis (majority regained ≥25% within ~1 year). Lean-mass changes: STEP 1 / SUSTAIN 8 body-composition data and Neeland et al., “Changes in lean body mass with GLP-1-based therapies,” Diabetes, Obesity and Metabolism 2024 (estimates vary; ~15–40% of loss as lean mass). Muscle preservation via protein and resistance training: established weight-management physiology. The Incretin Effect: What is it?